Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Biobehavioral Interactions between Endocannabinoid and Hypothalamicpituitary- adrenal Systems in Psychosis: A Systematic Review

Author(s): Marco Colizzi*, Riccardo Bortoletto, Giulia Antolini, Sagnik Bhattacharyya, Matteo Balestrieri and Marco Solmi*

Volume 22, Issue 3, 2024

Published on: 04 August, 2023

Page: [495 - 520] Pages: 26

DOI: 10.2174/1570159X21666230801150032

Price: $65

Abstract

Background: The diathesis-stress paradigm and the cannabinoid-hypothesis have been proposed as possible pathophysiological models of schizophrenia. However, they have historically been studied independently of each other.

Objective: This PRISMA 2020-compliant systematic review aimed at reappraising the interplay between the hypothalamic-pituitary-adrenal (HPA) axis and the endocannabinoid (eCB) system in psychosis- spectrum disorder risk and outcome.

Methods: All pathophysiological and outcome clinical studies, concomitantly evaluating the two systems in psychosis-spectrum disorder risk and different stages of illness, were gathered from electronic databases (Pubmed, Web of Science, and Scopus), and discussed.

Results: 41 eligible outputs were extracted, focusing on at least a biological measure (9 HPA-related studies: 4 eCB-interventional, 1 HPA-interventional, 1 both HPA-interventional and non-interventional, 3 non-interventional; 2 eCB-related studies: non-interventional), environmental measures only (29 studies: 1 eCB- interventional, 28 non-interventional), and genetic measures (1 study: non-interventional). Independent contributions of aberrancies in the two systems to the physiopathology and outcome of psychosis were confirmed. Also, concomitant alterations in the two systems, either genetically defined (e.g., CNR1 genetic variation), biologically determined (e.g., dysfunctional HPA axis or endocannabinoid signaling), or behaviorally imputed (e.g., cannabis use, stress exposure, and response), were consistently reported in psychosis. Further, a complex biobehavioral perturbation was revealed not only within each system (e.g., cannabis use affecting the eCB tone, stress exposure affecting the HPA axis), but also across the two systems (e.g., THC affecting the HPA axis, childhood trauma affecting the endocannabinoid signaling).

Conclusion: There is a need to concomitantly study the two systems’ mechanistic contribution to psychosis in order to establish more refined biological relevance.

« Previous
Graphical Abstract

[1]
Duncan, G.E.; Sheitman, B.B.; Lieberman, J.A. An integrated view of pathophysiological models of schizophrenia. Brain Res. Brain Res. Rev., 1999, 29(2-3), 250-264.
[http://dx.doi.org/10.1016/S0165-0173(99)00002-8] [PMID: 10209235]
[2]
Arango, C.; Dragioti, E.; Solmi, M.; Cortese, S.; Domschke, K.; Murray, R.M.; Jones, P.B.; Uher, R.; Carvalho, A.F.; Reichenberg, A.; Shin, J.I.I.; Andreassen, O.A.; Correll, C.U.; Fusar-Poli, P. Risk and protective factors for mental disorders beyond genetics: An evidence-based atlas. World Psychiatry, 2021, 20(3), 417-436.
[http://dx.doi.org/10.1002/wps.20894] [PMID: 34505386]
[3]
Dragioti, E.; Radua, J.; Solmi, M.; Arango, C.; Oliver, D.; Cortese, S.; Jones, P.B.; Il Shin, J.; Correll, C.U.; Fusar-Poli, P. Global population attributable fraction of potentially modifiable risk factors for mental disorders: A meta-umbrella systematic review. Mol. Psychiatry, 2022, 27(8), 3510-3519.
[http://dx.doi.org/10.1038/s41380-022-01586-8] [PMID: 35484237]
[4]
Lieberman, J.; Sheitman, B.B.; Kinon, B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology, 1997, 17(4), 205-229.
[http://dx.doi.org/10.1016/S0893-133X(97)00045-6] [PMID: 9326746]
[5]
Beards, S.; Gayer-Anderson, C.; Borges, S.; Dewey, M.E.; Fisher, H.L.; Morgan, C. Life events and psychosis: A review and meta-analysis. Schizophr. Bull., 2013, 39(4), 740-747.
[http://dx.doi.org/10.1093/schbul/sbt065] [PMID: 23671196]
[6]
Moore, T.H.M.; Zammit, S.; Lingford-Hughes, A.; Barnes, T.R.E.; Jones, P.B.; Burke, M.; Lewis, G. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet, 2007, 370(9584), 319-328.
[http://dx.doi.org/10.1016/S0140-6736(07)61162-3] [PMID: 17662880]
[7]
Meehl, P.E. Schizotaxia, schizotypy, schizophrenia. Am. Psychol., 1962, 17(12), 827-838.
[http://dx.doi.org/10.1037/h0041029]
[8]
Appiah-Kusi, E.; Leyden, E.; Parmar, S.; Mondelli, V.; McGuire, P.; Bhattacharyya, S. Abnormalities in neuroendocrine stress response in psychosis: The role of endocannabinoids. Psychol. Med., 2016, 46(1), 27-45.
[http://dx.doi.org/10.1017/S0033291715001786] [PMID: 26370602]
[9]
Day, R. Life events and schizophrenia: The “triggering” hypothesis. Acta Psychiatr. Scand., 1981, 64(2), 97-122.
[http://dx.doi.org/10.1111/j.1600-0447.1981.tb00765.x] [PMID: 7032227]
[10]
Corcoran, C.; Walker, E.; Huot, R.; Mittal, V.; Tessner, K.; Kestler, L.; Malaspina, D. The stress cascade and schizophrenia: Etiology and onset. Schizophr. Bull., 2003, 29(4), 671-692.
[http://dx.doi.org/10.1093/oxfordjournals.schbul.a007038] [PMID: 14989406]
[11]
Walker, E.F.; Diforio, D. Schizophrenia: A neural diathesis-stress model. Psychol. Rev., 1997, 104(4), 667-685.
[http://dx.doi.org/10.1037/0033-295X.104.4.667] [PMID: 9337628]
[12]
Pruessner, M.; Cullen, A.E.; Aas, M.; Walker, E.F. The neural diathesis-stress model of schizophrenia revisited: An update on recent findings considering illness stage and neurobiological and methodological complexities. Neurosci. Biobehav. Rev., 2017, 73, 191-218.
[http://dx.doi.org/10.1016/j.neubiorev.2016.12.013] [PMID: 27993603]
[13]
Cullen, A.E.; Rai, S.; Vaghani, M.S.; Mondelli, V.; McGuire, P. Cortisol responses to naturally occurring psychosocial stressors across the psychosis spectrum: a systematic review and meta-analysis. Front. Psychiatry, 2020, 11, 513.
[http://dx.doi.org/10.3389/fpsyt.2020.00513] [PMID: 32595532]
[14]
Murray, R.M.; Morrison, P.D.; Henquet, C.; Forti, M.D. Cannabis, the mind and society: The hash realities. Nat. Rev. Neurosci., 2007, 8(11), 885-895.
[http://dx.doi.org/10.1038/nrn2253] [PMID: 17925811]
[15]
Zammit, S.; Moore, T.H.M.; Lingford-Hughes, A.; Barnes, T.R.E.; Jones, P.B.; Burke, M.; Lewis, G. Effects of cannabis use on outcomes of psychotic disorders: Systematic review. Br. J. Psychiatry, 2008, 193(5), 357-363.
[http://dx.doi.org/10.1192/bjp.bp.107.046375] [PMID: 18978312]
[16]
Gage, S.H.; Jones, H.J.; Burgess, S.; Bowden, J.; Davey Smith, G.; Zammit, S.; Munafò, M.R. Assessing causality in associations between cannabis use and schizophrenia risk: A two-sample Mendelian randomization study. Psychol. Med., 2017, 47(5), 971-980.
[http://dx.doi.org/10.1017/S0033291716003172] [PMID: 27928975]
[17]
Colizzi, M.; Murray, R. Cannabis and psychosis: what do we know and what should we do? Br. J. Psychiatry, 2018, 212(4), 195-196.
[http://dx.doi.org/10.1192/bjp.2018.1] [PMID: 29557759]
[18]
Colizzi, M.; Bhattacharyya, S. Neurocognitive effects of cannabis: Lessons learned from human experimental studies. Prog. Brain Res.,, 2018, 242, 179-216.
[http://dx.doi.org/10.1016/bs.pbr.2018.08.010] [PMID: 30471680]
[19]
Colizzi, M.; Bhattacharyya, S. Risk factors for psychosis: Paradigms, mechanisms, and prevention; Thompson, A.D; Broome, M.R., Ed.; Academic Press: Cambridge, USA, 2020, pp. 305-331.
[20]
Minichino, A.; Senior, M.; Brondino, N.; Zhang, S.H.; Godlewska, B.R.; Burnet, P.W.J.; Cipriani, A.; Lennox, B.R. Measuring disturbance of the endocannabinoid system in psychosis. JAMA Psychiatry, 2019, 76(9), 914-923.
[http://dx.doi.org/10.1001/jamapsychiatry.2019.0970] [PMID: 31166595]
[21]
Micale, V.; Drago, F. Endocannabinoid system, stress and HPA axis. Eur. J. Pharmacol., 2018, 834, 230-239.
[http://dx.doi.org/10.1016/j.ejphar.2018.07.039] [PMID: 30036537]
[22]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021, 372(71), n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[23]
Colizzi, M.; McGuire, P.; Pertwee, R.G.; Bhattacharyya, S. Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. Neurosci. Biobehav. Rev., 2016, 64, 359-381.
[http://dx.doi.org/10.1016/j.neubiorev.2016.03.010] [PMID: 26987641]
[24]
Colizzi, M.; Bortoletto, R.; Costa, R.; Bhattacharyya, S.; Balestrieri, M. The autism-psychosis continuum conundrum: Exploring the role of the endocannabinoid system. Int. J. Environ. Res. Public Health, 2022, 19(9), 5616.
[http://dx.doi.org/10.3390/ijerph19095616] [PMID: 35565034]
[25]
West, S.; King, V.; Carey, T.S.; Lohr, K.N.; McKoy, N.; Sutton, S.F.; Lux, L. Systems to rate the strength of scientific evidence. Evid. Rep. Technol. Assess., 2002, (47), 1-11.
[PMID: 11979732]
[26]
D’Souza, D.C.; Abi-Saab, W.M.; Madonick, S.; Forselius-Bielen, K.; Doersch, A.; Braley, G.; Gueorguieva, R.; Cooper, T.B.; Krystal, J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol. Psychiatry, 2005, 57(6), 594-608.
[http://dx.doi.org/10.1016/j.biopsych.2004.12.006] [PMID: 15780846]
[27]
Appiah-Kusi, E.; Petros, N.; Wilson, R.; Colizzi, M.; Bossong, M.G.; Valmaggia, L.; Mondelli, V.; McGuire, P.; Bhattacharyya, S. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology , 2020, 237(4), 1121-1130.
[http://dx.doi.org/10.1007/s00213-019-05442-6] [PMID: 31915861]
[28]
Davies, C.; Appiah-Kusi, E.; Wilson, R.; Blest-Hopley, G.; Bossong, M.G.; Valmaggia, L.; Brammer, M.; Perez, J.; Allen, P.; Murray, R.M.; McGuire, P.; Bhattacharyya, S. Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: A preliminary report. Eur. Arch. Psychiatry Clin. Neurosci., 2022, 272(3), 461-475.
[http://dx.doi.org/10.1007/s00406-021-01318-z] [PMID: 34480630]
[29]
Colizzi, M.; Weltens, N.; Lythgoe, D.J.; Williams, S.C.; Van Oudenhove, L.; Bhattacharyya, S. Differential sensitivity to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol associated with its differential acute effects on glial function and cortisol. Psychol. Med., 2022, 52(11), 2024-2031.
[PMID: 33107418]
[30]
Monteleone, P.; Filippo, C.D.; Fabrazzo, M.; Milano, W.; Martiadis, V.; Corrivetti, G.; Monteleone, A.M.; Maj, M. Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. Psychiatry Res., 2014, 215(2), 263-267.
[http://dx.doi.org/10.1016/j.psychres.2013.12.016] [PMID: 24388728]
[31]
Labad, J.; Ortega, L.; Cabezas, Á.; Montalvo, I.; Arranz, S.; Algora, M.J.; Solé, M.; Martorell, L.; Vilella, E.; Sánchez-Gistau, V. Hypothalamic-pituitary-adrenal axis function and exposure to stress factors and cannabis use in recent-onset psychosis. World J. Biol. Psychiatry, 2020, 21(7), 564-571.
[http://dx.doi.org/10.1080/15622975.2019.1628301] [PMID: 31244371]
[32]
Carol, E.E.; Spencer, R.L.; Mittal, V.A. The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis. Psychoneuroendocrinology, 2017, 83, 58-64.
[http://dx.doi.org/10.1016/j.psyneuen.2017.04.017] [PMID: 28595088]
[33]
Schifani, C.; Pruessner, J.; Tseng, H.H.; Rao, N.; Tagore, A.; Wilson, A.A.; Houle, S.; Rusjan, P.M.; Mizrahi, R. Stress‐induced cortical dopamine response is altered in subjects at clinical high risk for psychosis using cannabis. Addict. Biol., 2020, 25(4), e12812.
[http://dx.doi.org/10.1111/adb.12812] [PMID: 31389139]
[34]
Mizrahi, R.; Kenk, M.; Suridjan, I.; Boileau, I.; George, T.P.; McKenzie, K.; Wilson, A.A.; Houle, S.; Rusjan, P. Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology, 2014, 39(6), 1479-1489.
[http://dx.doi.org/10.1038/npp.2013.347] [PMID: 24385130]
[35]
Newman-Taylor, K.; Richardson, T.; Lees, R.; Petrilli, K.; Bolderston, H.; Hindocha, C.; Freeman, T.P.; Bloomfield, M.A.P. Cognitive fusion as a candidate psychological vulnerability factor for psychosis: An experimental study of acute ∆9-tetrahydrocannabinol (THC) intoxication. Psychosis, 2021, 13(2), 167-174.
[http://dx.doi.org/10.1080/17522439.2020.1853203]
[36]
Baudin, G.; Godin, O.; Lajnef, M.; Aouizerate, B.; Berna, F.; Brunel, L.; Capdevielle, D.; Chereau, I.; Dorey, J.M.; Dubertret, C.; Dubreucq, J.; Faget, C.; Fond, G.; Gabayet, F.; Laouamri, H.; Lancon, C.; Le Strat, Y.; Tronche, A.M.; Misdrahi, D.; Rey, R.; Passerieux, C.; Schandrin, A.; Urbach, M.; Vidalhet, P.; Llorca, P.M.; Schürhoff, F.; Collaborators, F.A.C.E.S.F-S. Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia. Schizophr. Res., 2016, 175(1-3), 161-167.
[http://dx.doi.org/10.1016/j.schres.2016.04.042] [PMID: 27209524]
[37]
Newman-Taylor, K.; Richardson, T.; Sood, M.; Sopp, M.; Perry, E.; Bolderston, H. Cognitive mechanisms in cannabis-related paranoia; Initial testing and model proposal. Psychosis, 2020, 12(4), 314-327.
[http://dx.doi.org/10.1080/17522439.2020.1757742]
[38]
Lemvigh, C.; Brouwer, R.; Hilker, R.; Anhøj, S.; Baandrup, L.; Pantelis, C.; Glenthøj, B.; Fagerlund, B. The relative and interactive impact of multiple risk factors in schizophrenia spectrum disorders: A combined register-based and clinical twin study. Psychol. Med., 2021, 53(4), 1266-1276.
[http://dx.doi.org/10.1017/S0033291721002749] [PMID: 35822354]
[39]
del Re, E.C.; Yassin, W.; Zeng, V.; Keedy, S.; Alliey-Rodriguez, N.; Ivleva, E.; Hill, S.; Rychagov, N.; McDowell, J.E.; Bishop, J.R.; Mesholam-Gately, R.; Merola, G.; Lizano, P.; Gershon, E.; Pearlson, G.; Sweeney, J.A.; Clementz, B.; Tamminga, C.; Keshavan, M. Characterization of childhood trauma, hippocampal mediation and Cannabis use in a large dataset of psychosis and non-psychosis individuals. . Schizophr Res., 2023, 255, 102-109.
[http://dx.doi.org/ 10.1016/j.schres.2023.03.029] [PMID: 36989667]
[40]
De Pradier, M.; Gorwood, P.; Beaufils, B.; Adès, J.; Dubertret, C. Influence of the serotonin transporter gene polymorphism, cannabis and childhood sexual abuse on phenotype of bipolar disorder: A preliminary study. Eur. Psychiatry, 2010, 25(6), 323-327.
[http://dx.doi.org/10.1016/j.eurpsy.2009.10.002] [PMID: 20434316]
[41]
Arranz, S.; Monferrer, N.; Jose Algora, M.; Cabezas, A.; Sole, M.; Vilella, E.; Labad, J.; Sanchez-Gistau, V. The relationship between the level of exposure to stress factors and cannabis in recent onset psychosis. Schizophr. Res., 2018, 201, 352-359.
[http://dx.doi.org/10.1016/j.schres.2018.04.040] [PMID: 29743139]
[42]
Barrigón, M.L.; Diaz, F.J.; Gurpegui, M.; Ferrin, M.; Salcedo, M.D.; Moreno-Granados, J.; Cervilla, J.A.; Ruiz-Veguilla, M. Childhood trauma as a risk factor for psychosis: A sib-pair study. J. Psychiatr. Res., 2015, 70, 130-136.
[http://dx.doi.org/10.1016/j.jpsychires.2015.08.017] [PMID: 26424432]
[43]
Sideli, L.; Fisher, H.L.; Murray, R.M.; Sallis, H.; Russo, M.; Stilo, S.A.; Paparelli, A.; Wiffen, B.D.R.; O’Connor, J.A.; Pintore, S.; Ferraro, L.; La Cascia, C.; La Barbera, D.; Morgan, C.; Di Forti, M. Interaction between cannabis consumption and childhood abuse in psychotic disorders: preliminary findings on the role of different patterns of cannabis use. Early Interv. Psychiatry, 2018, 12(2), 135-142.
[http://dx.doi.org/10.1111/eip.12285] [PMID: 26560802]
[44]
Lu, Y.; Marshall, C.; Cadenhead, K.S.; Cannon, T.D.; Cornblatt, B.A.; McGlashan, T.H.; Perkins, D.O.; Seidman, L.J.; Tsuang, M.T.; Walker, E.F.; Woods, S.W.; Bearden, C.E.; Mathalon, D.; Addington, J. Perceptual abnormalities in clinical high risk youth and the role of trauma, cannabis use and anxiety. Psychiatry Res., 2017, 258, 462-468.
[http://dx.doi.org/10.1016/j.psychres.2017.08.045] [PMID: 28886901]
[45]
Houston, J.E.; Murphy, J.; Adamson, G.; Stringer, M.; Shevlin, M. Childhood sexual abuse, early cannabis use, and psychosis: Testing an interaction model based on the National Comorbidity Survey. Schizophr. Bull., 2007, 34(3), 580-585.
[http://dx.doi.org/10.1093/schbul/sbm127] [PMID: 18024467]
[46]
Harley, M.; Kelleher, I.; Clarke, M.; Lynch, F.; Arseneault, L.; Connor, D.; Fitzpatrick, C.; Cannon, M. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol. Med., 2010, 40(10), 1627-1634.
[http://dx.doi.org/10.1017/S0033291709991966] [PMID: 19995476]
[47]
Konings, M.; Stefanis, N.; Kuepper, R.; de Graaf, R.; Have, M.; van Os, J.; Bakoula, C.; Henquet, C. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol. Med., 2012, 42(1), 149-159.
[http://dx.doi.org/10.1017/S0033291711000973] [PMID: 21676285]
[48]
Murphy, J.; Houston, J.E.; Shevlin, M.; Adamson, G. Childhood sexual trauma, cannabis use and psychosis: Statistically controlling for pre-trauma psychosis and psychopathology. Soc. Psychiatry Psychiatr. Epidemiol., 2013, 48(6), 853-861.
[http://dx.doi.org/10.1007/s00127-012-0592-8] [PMID: 23052424]
[49]
Kuepper, R.; Henquet, C.; Lieb, R.; Wittchen, H.U.; van Os, J. Non-replication of interaction between cannabis use and trauma in predicting psychosis. Schizophr. Res., 2011, 131(1-3), 262-263.
[http://dx.doi.org/10.1016/j.schres.2011.06.012] [PMID: 21745727]
[50]
Cougnard, A.; Marcelis, M.; Myin-Germeys, I.; De Graaf, R.; Vollebergh, W.; Krabbendam, L.; Lieb, R.; Wittchen, H.U.; Henquet, C.; Spauwen, J.; Van Os, J. Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness–persistence model. Psychol. Med., 2007, 37(4), 513-527.
[http://dx.doi.org/10.1017/S0033291706009731] [PMID: 17288646]
[51]
Houston, J.E.; Murphy, J.; Shevlin, M.; Adamson, G. Cannabis use and psychosis: Re-visiting the role of childhood trauma. Psychol. Med., 2011, 41(11), 2339-2348.
[http://dx.doi.org/10.1017/S0033291711000559] [PMID: 21557896]
[52]
Daly, M. Letter to the Editor: Childhood trauma may combine synergistically with stimulant use rather than cannabis use to predict psychosis. In: Psychol. Med; , 2012; 42, pp. (2)445-446.
[http://dx.doi.org/10.1017/S0033291711002546]] [PMID: 22085776]
[53]
van Nierop, M.; van Os, J.; Gunther, N.; van Zelst, C.; de Graaf, R.; ten Have, M.; van Dorsselaer, S.; Bak, M.; Myin-Germeys, I.; van Winkel, R. Does social defeat mediate the association between childhood trauma and psychosis? Evidence from the NEMESIS-2 Study. Acta Psychiatr. Scand., 2014, 129(6), 467-476.
[http://dx.doi.org/10.1111/acps.12212] [PMID: 24571736]
[54]
Morgan, C.; Reininghaus, U.; Reichenberg, A.; Frissa, S.; Hotopf, M.; Hatch, S.L. Adversity, cannabis use and psychotic experiences: Evidence of cumulative and synergistic effects. Br. J. Psychiatry, 2014, 204(5), 346-353.
[http://dx.doi.org/10.1192/bjp.bp.113.134452] [PMID: 24627297]
[55]
Guloksuz, S.; van Nierop, M.; Lieb, R.; van Winkel, R.; Wittchen, H.U.; van Os, J. Evidence that the presence of psychosis in non-psychotic disorder is environment-dependent and mediated by severity of non-psychotic psychopathology. Psychol. Med., 2015, 45(11), 2389-2401.
[http://dx.doi.org/10.1017/S0033291715000380] [PMID: 25804288]
[56]
Pries, L.K.; Guloksuz, S.; ten Have, M.; de Graaf, R.; van Dorsselaer, S.; Gunther, N.; Rauschenberg, C.; Reininghaus, U.; Radhakrishnan, R.; Bak, M.; Rutten, B.P.F.; van Os, J. Evidence that environmental and familial risks for psychosis additively impact a multidimensional subthreshold psychosis syndrome. Schizophr. Bull., 2018, 44(4), 710-719.
[http://dx.doi.org/10.1093/schbul/sby051] [PMID: 29701807]
[57]
Frydecka, D.; Misiak, B.; Kotowicz, K.; Pionke, R. Krężołek, M.; Cechnicki, A.; Gawęda, Ł. The interplay between childhood trauma, cognitive biases, and cannabis use on the risk of psychosis in nonclinical young adults in Poland. Eur. Psychiatry, 2020, 63(1), e35.
[http://dx.doi.org/10.1192/j.eurpsy.2020.31] [PMID: 32200775]
[58]
Kirli, U.; Binbay, T.; Alptekin, K.; Kayahan, B.; Elbi, H. The relationship between alcohol-cannabis use and stressful events with the development of incident clinical psychosis in a community-based prospective cohort. Turk Psikiyatr. Derg., 2021, 32(4), 235-245.
[http://dx.doi.org/10.5080/u26410] [PMID: 34964097]
[59]
Daly, M. Letter to the Editor: Poor childhood mental health may explain linkages between trauma, cannabis use and later psychotic experiences. In: Psychol. Med; , 2011; 41, pp. (9)2012-2014.
[http://dx.doi.org/10.1017/S0033291711001024]] [PMID: 21676284]
[60]
Alemany, S.; Arias, B.; Fatjó-Vilas, M.; Villa, H.; Moya, J.; Ibáñez, M.I.; Ortet, G.; Gastó, C.; Fañanás, L. Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr. Scand., 2014, 129(1), 54-62.
[http://dx.doi.org/10.1111/acps.12108] [PMID: 23445265]
[61]
Vinkers, C.H.; Van Gastel, W.A.; Schubart, C.D.; Van Eijk, K.R.; Luykx, J.J.; Van Winkel, R.; Joëls, M.; Ophoff, R.A.; Boks, M.P.M.; Bruggeman, R.; Cahn, W.; de Haan, L.; Kahn, R.S.; Meijer, C.J.; Myin-Germeys, I.; van Os, J.; Wiersma, D. The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val158Met polymorphism. Schizophr. Res., 2013, 150(1), 303-311.
[http://dx.doi.org/10.1016/j.schres.2013.07.020] [PMID: 23954148]
[62]
DeRosse, P.; Ikuta, T.; Peters, B.D.; Karlsgodt, K.H.; Szeszko, P.R.; Malhotra, A.K. Adding insult to injury: Childhood and adolescent risk factors for psychosis predict lower fractional anisotropy in the superior longitudinal fasciculus in healthy adults. Psychiatry Res. Neuroimaging, 2014, 224(3), 296-302.
[http://dx.doi.org/10.1016/j.pscychresns.2014.09.001] [PMID: 25277095]
[63]
Carlyle, M.; Constable, T.; Walter, Z.C.; Wilson, J.; Newland, G.; Hides, L. Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users. Schizophr. Res., 2021, 238, 178-184.
[http://dx.doi.org/10.1016/j.schres.2021.10.011] [PMID: 34717186]
[64]
Monterrubio, S.; Solowij, N.; Meyer, B.J.; Turner, N. Fatty acid relationships in former cannabis users with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(2), 280-285.
[http://dx.doi.org/10.1016/j.pnpbp.2005.08.013] [PMID: 16236415]
[65]
Appiah-Kusi, E.; Wilson, R.; Colizzi, M.; Foglia, E.; Klamerus, E.; Caldwell, A.; Bossong, M.G.; McGuire, P.; Bhattacharyya, S. Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids. Psychol. Med., 2019, 50(11), 1862-1871.
[PMID: 31422779]
[66]
Rojnic Kuzman, M.; Bosnjak Kuharic, D.; Ganoci, L.; Makaric, P.; Kekin, I.; Rossini Gajsak, L.; Prpic, N.; Bozina, T.; Bajic, Z.; Bozina, N. Association of CNR1 genotypes with changes in neurocognitive performance after eighteen-month treatment in patients with first-episode psychosis. Eur. Psychiatry, 2019, 61, 88-96.
[http://dx.doi.org/10.1016/j.eurpsy.2019.07.004] [PMID: 31398679]
[67]
Martland, N.; Martland, R.; Cullen, A.E.; Bhattacharyya, S. Are adult stressful life events associated with psychotic relapse? A systematic review of 23 studies. Psychol. Med., 2020, 50(14), 2302-2316.
[http://dx.doi.org/10.1017/S0033291720003554] [PMID: 33054892]
[68]
Howes, O.; McCutcheon, R.; Stone, J. Glutamate and dopamine in schizophrenia: An update for the 21 st century. J. Psychopharmacol., 2015, 29(2), 97-115.
[http://dx.doi.org/10.1177/0269881114563634] [PMID: 25586400]
[69]
Llorente-Berzal, A.; Terzian, A.L.B.; di Marzo, V.; Micale, V.; Viveros, M.P.; Wotjak, C.T. 2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. Psychopharmacology , 2015, 232(15), 2811-2825.
[http://dx.doi.org/10.1007/s00213-015-3917-y] [PMID: 25814137]
[70]
Micale, V.; Stepan, J.; Jurik, A.; Pamplona, F.A.; Marsch, R.; Drago, F.; Eder, M.; Wotjak, C.T. Extinction of avoidance behavior by safety learning depends on endocannabinoid signaling in the hippocampus. J. Psychiatr. Res., 2017, 90, 46-59.
[http://dx.doi.org/10.1016/j.jpsychires.2017.02.002] [PMID: 28222356]
[71]
Terzian, A.L.; Drago, F.; Wotjak, C.T.; Micale, V. The dopamine and cannabinoid interaction in the modulation of emotions and cognition: Assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors. Front. Behav. Neurosci., 2011, 5, 49.
[http://dx.doi.org/10.3389/fnbeh.2011.00049] [PMID: 21887137]
[72]
Terzian, A.L.B.; Micale, V.; Wotjak, C.T. Cannabinoid receptor type 1 receptors on GABAergic vs. glutamatergic neurons differentially gate sex-dependent social interest in mice. Eur. J. Neurosci., 2014, 40(1), 2293-2298.
[http://dx.doi.org/10.1111/ejn.12561] [PMID: 24698342]
[73]
Bhattacharyya, S.; Morrison, P.D.; Fusar-Poli, P.; Martin-Santos, R.; Borgwardt, S.; Winton-Brown, T.; Nosarti, C.; O’ Carroll, C.M.; Seal, M.; Allen, P.; Mehta, M.A.; Stone, J.M.; Tunstall, N.; Giampietro, V.; Kapur, S.; Murray, R.M.; Zuardi, A.W.; Crippa, J.A.; Atakan, Z.; McGuire, P.K. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 2010, 35(3), 764-774.
[http://dx.doi.org/10.1038/npp.2009.184] [PMID: 19924114]
[74]
Leweke, F.M.; Piomelli, D.; Pahlisch, F.; Muhl, D.; Gerth, C.W.; Hoyer, C.; Klosterkötter, J.; Hellmich, M.; Koethe, D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry, 2012, 2(3), e94.
[http://dx.doi.org/10.1038/tp.2012.15] [PMID: 22832859]
[75]
Rodrigues da Silva, N.; Gomes, F.V.; Sonego, A.B.; Silva, N.R.; Guimarães, F.S. Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors. Pharmacol. Res., 2020, 156, 104749.
[http://dx.doi.org/10.1016/j.phrs.2020.104749] [PMID: 32151683]
[76]
Seeman, P. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl. Psychiatry, 2016, 6(10), e920.
[http://dx.doi.org/10.1038/tp.2016.195] [PMID: 27754480]
[77]
Stark, T.; Di Bartolomeo, M.; Di Marco, R.; Drazanova, E.; Platania, C.B.M.; Iannotti, F.A.; Ruda-Kucerova, J.; D’Addario, C.; Kratka, L.; Pekarik, V.; Piscitelli, F.; Babinska, Z.; Fedotova, J.; Giurdanella, G.; Salomone, S.; Sulcova, A.; Bucolo, C.; Wotjak, C.T.; Starcuk, Z., Jr; Drago, F.; Mechoulam, R.; Di Marzo, V.; Micale, V. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochem. Pharmacol., 2020, 177, 114004.
[http://dx.doi.org/10.1016/j.bcp.2020.114004] [PMID: 32360362]
[78]
Di Bartolomeo, M.; Stark, T.; Maurel, O.M.; Iannotti, F.A.; Kuchar, M.; Ruda-Kucerova, J.; Piscitelli, F.; Laudani, S.; Pekarik, V.; Salomone, S.; Arosio, B.; Mechoulam, R.; Maccarrone, M.; Drago, F.; Wotjak, C.T.; Di Marzo, V.; Vismara, M.; Dell’Osso, B.; D’Addario, C.; Micale, V. Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatalΔ 9-tetrahydrocannabinol-exposed rats. Pharmacol. Res., 2021, 164, 105357.
[http://dx.doi.org/10.1016/j.phrs.2020.105357] [PMID: 33285233]
[79]
Stark, T.; Ruda-Kucerova, J.; Iannotti, F.A.; D’Addario, C.; Di Marco, R.; Pekarik, V.; Drazanova, E.; Piscitelli, F.; Bari, M.; Babinska, Z.; Giurdanella, G.; Di Bartolomeo, M.; Salomone, S.; Sulcova, A.; Maccarrone, M.; Wotjak, C.T.; Starcuk, Z., Jr; Drago, F.; Mechoulam, R.; Di Marzo, V.; Micale, V. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology, 2019, 146, 212-221.
[http://dx.doi.org/10.1016/j.neuropharm.2018.11.035] [PMID: 30496751]
[80]
Stark, T.; Di Martino, S.; Drago, F.; Wotjak, C.T.; Micale, V. Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacol. Res., 2021, 174, 105938.
[http://dx.doi.org/10.1016/j.phrs.2021.105938] [PMID: 34655773]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy